Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin.

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin. Blood. 2025 Jul 24; 146(4):471-481.

View in: PubMed

subject areas

Antineoplastic Agents, Immunological
Cell Differentiation
Cell Line, Tumor
Drug Resistance, Neoplasm
Gene Expression Regulation, Leukemic
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Sialic Acid Binding Ig-like Lectin 2
Trans-Activators
Transcription, Genetic

authors with profiles

Wendy Stock